FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3195831375> ?p ?o ?g. }

• W3195831375 endingPage "25" @default.
• W3195831375 startingPage "15" @default.
• W3195831375 abstract "The clinical outcome of patients with human epidermal growth factor receptor 2 (HER2) amplified breast carcinoma (BC) has improved with the development of anti-HER2 targeted therapies. However, patients can experience disease recurrence after curative intent and disease progression in the metastatic setting. In the current era of evolving immunotherapy agents, the understanding of the immune response against HER2 tumor cells developed by anti-HER2 antibodies (Abs) is rapidly evolving. Trastuzumab therapy promotes Natural Killer (NK) cell activation in patients with BC overexpressing HER2, indicating that the efficacy of short-term trastuzumab monotherapy, albeit direct inhibition of HER, could also be related with antibody-dependent cell-mediated cytotoxicity (ADCC). Currently, dual HER2 blockade using trastuzumab and pertuzumab is the standard of care in early and advanced disease as this combination could confer an additive effect in ADCC. In patients with disease relapse or progression, ADCC may be hampered by several factors such as FcγRIIIa polymorphism and an immunosuppressive environment, among others. Hence, new drug development strategies are being investigated aiming to boost the ADCC response triggered by anti-HER2 therapy. In this review, we summarize these strategies and the rationale, through mAbs engineering and combinatorial strategies, focusing on clinical results and ongoing trials." @default.
• W3195831375 created "2021-08-30" @default.
• W3195831375 creator A5033156236 @default.
• W3195831375 creator A5045931580 @default.
• W3195831375 creator A5075136610 @default.
• W3195831375 creator A5088670404 @default.
• W3195831375 creator A5090411527 @default.
• W3195831375 date "2021-12-01" @default.
• W3195831375 modified "2023-10-18" @default.
• W3195831375 title "Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era" @default.
• W3195831375 cites W1529809181 @default.
• W3195831375 cites W1541594543 @default.
• W3195831375 cites W1589766395 @default.
• W3195831375 cites W1601925808 @default.
• W3195831375 cites W1820495241 @default.
• W3195831375 cites W1829424702 @default.
• W3195831375 cites W1896751847 @default.
• W3195831375 cites W1903287340 @default.
• W3195831375 cites W1967512987 @default.
• W3195831375 cites W1967581879 @default.
• W3195831375 cites W1968321644 @default.
• W3195831375 cites W1968590850 @default.
• W3195831375 cites W1975793384 @default.
• W3195831375 cites W1979343444 @default.
• W3195831375 cites W1981910809 @default.
• W3195831375 cites W1987029228 @default.
• W3195831375 cites W1991644988 @default.
• W3195831375 cites W1993869378 @default.
• W3195831375 cites W1998414899 @default.
• W3195831375 cites W2004794726 @default.
• W3195831375 cites W2006710185 @default.
• W3195831375 cites W2010034291 @default.
• W3195831375 cites W2011944525 @default.
• W3195831375 cites W2014208459 @default.
• W3195831375 cites W2025950737 @default.
• W3195831375 cites W2030307609 @default.
• W3195831375 cites W2040914801 @default.
• W3195831375 cites W2041483436 @default.
• W3195831375 cites W2049345643 @default.
• W3195831375 cites W2056019889 @default.
• W3195831375 cites W2059208538 @default.
• W3195831375 cites W2060974366 @default.
• W3195831375 cites W2070109360 @default.
• W3195831375 cites W2076345036 @default.
• W3195831375 cites W2094901950 @default.
• W3195831375 cites W2100527196 @default.
• W3195831375 cites W2104239861 @default.
• W3195831375 cites W2109502548 @default.
• W3195831375 cites W2115175735 @default.
• W3195831375 cites W2118371851 @default.
• W3195831375 cites W2122080125 @default.
• W3195831375 cites W2126240154 @default.
• W3195831375 cites W2128824801 @default.
• W3195831375 cites W2129397990 @default.
• W3195831375 cites W2132853354 @default.
• W3195831375 cites W2138498230 @default.
• W3195831375 cites W2148775307 @default.
• W3195831375 cites W2162904392 @default.
• W3195831375 cites W2165003903 @default.
• W3195831375 cites W2172005924 @default.
• W3195831375 cites W2205886515 @default.
• W3195831375 cites W2213952892 @default.
• W3195831375 cites W2247021348 @default.
• W3195831375 cites W2275274887 @default.
• W3195831375 cites W2314772071 @default.
• W3195831375 cites W2460150844 @default.
• W3195831375 cites W2473435857 @default.
• W3195831375 cites W2479910958 @default.
• W3195831375 cites W2496306054 @default.
• W3195831375 cites W2546973056 @default.
• W3195831375 cites W2552090747 @default.
• W3195831375 cites W2591005579 @default.
• W3195831375 cites W2594312824 @default.
• W3195831375 cites W2596192643 @default.
• W3195831375 cites W2610816311 @default.
• W3195831375 cites W2673643310 @default.
• W3195831375 cites W2740852255 @default.
• W3195831375 cites W2745792339 @default.
• W3195831375 cites W2762388141 @default.
• W3195831375 cites W2764263929 @default.
• W3195831375 cites W2766673799 @default.
• W3195831375 cites W2766842037 @default.
• W3195831375 cites W2769847998 @default.
• W3195831375 cites W2794322099 @default.
• W3195831375 cites W2800269382 @default.
• W3195831375 cites W2802098245 @default.
• W3195831375 cites W2802789880 @default.
• W3195831375 cites W2884035880 @default.
• W3195831375 cites W2885605094 @default.
• W3195831375 cites W2890882011 @default.
• W3195831375 cites W2891365914 @default.
• W3195831375 cites W2892311857 @default.
• W3195831375 cites W2897992036 @default.
• W3195831375 cites W2902856530 @default.
• W3195831375 cites W2913250085 @default.
• W3195831375 cites W2913965697 @default.
• W3195831375 cites W2946946191 @default.
• W3195831375 cites W2947573449 @default.

• next